Intratumoral gene therapy versus intravenous gene therapy for distant metastasis control with 2-Diethylaminoethyl-Dextran Methyl Methacrylate Copolymer Non-Viral Vector-p53

Gene Therapy

Volumn 21, Issue 2, 2014, Pages 158-167

  Baliaka, A ^a   Zarogoulidis, P ^b,c   Domvri, K ^b   Hohenforst Schmidt, W ^d   Sakkas, A ^a   Huang, H ^e   Le Pivert, P ^f   Koliakos, G ^b   Koliakou, E ^b   Kouzi Koliakos, K ^b   Tsakiridis, K ^g   Chioti, A ^a   Siotou, E ^a   Cheva, A ^a   Zarogoulidis, K ^b   Sakkas, L ^a  

^a G PAPANICOLAOU HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

^f Interventional Drug Delivery Systems and Strategies (ID2S2)   (United States)

^g Cardiothoracic Surgery Department 'Saint Luke' Private Hospital   (Greece)

Author keywords

DDMC; Intratumoral; Intravenous; Lung cancer; P53; Vectors

Indexed keywords

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; DEAE-DEXTRAN; GENETIC THERAPY; METHYLMETHACRYLATE; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; PLASMIDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84893810417     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2013.68     Document Type: Article

References (91)

1. Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013; 382: 720-731.
2. Lee SY, Kang HG, Yoo SS, Kang YR, Choi YY, Lee WK et al. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy. Lung Cancer 2013; 82: 330-339.
3. Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: implications for clinical practice and open issues. Lung Cancer 2011; 72: 3-8.
4. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013; 31: 1039-1049.
5. Nelson V, Ziehr J, Agulnik M, Johnson M. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Oncol Targets Ther 2013; 6: 135-143.
6. Gadgeel SM, Wozniak A. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clin Lung Cancer 2013; 14: 322-332.
7. Darwiche K, Zarogoulidis P, Baehner K, Welter S, Tetzner R, Wohlschlaeger J et al. Assessment of SHOX2 methylation in EBUS-TBNA specimen improves accuracy in lung cancer staging. Ann Oncol 2013; 24: 2866-2870.
8. Zarogoulidis K, Papagiannis A, Ziogas E, Fahantidou E, Dermitzakis G, Gioulekas D et al. Management of chemotherapy-related anaemia with low-dose recombinant human erythropoietin in patients with small cell lung cancer. Eur J Cancer 1997; 33: 2428-2431.
9. Ihbe-Heffinger A, Paessens B, Berger K, Shlaen M, Bernard R, von Schilling C et al. The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care-an observational analysis on non-small-cell lung cancer patients. Support Care Cancer 2013; 21: 1665-1675.
10. Ong CK, Tan WC, Chan LC, Abdul Razak M. Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management. Med J Malaysia 2012; 67: 222-223.
11. Xie FJ, Zhao P, Zhang YP, Liu FY, Nie XL, Zhu YH et al. Adenovirus-mediated interferon-gamma gene therapy induced human pancreatic carcinoma Capan-2 cell apoptosis in vitro and in vivo. Anat Rec (Hoboken) 2013; 296: 604-610.
12. Zarogoulidis P, Chatzaki E, Hohenforst-Schmidt W, Goldberg EP, Galaktidou G, Kontakiotis T et al. Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review. Cancer Gene Ther 2012; 19: 593-600s.
13. Celikoglu F, Celikoglu SI, Goldberg EP. Bronchoscopic intratumoral chemotherapy of lung cancer. Lung Cancer 2008; 61: 1-12.
14. Zarogoulidis P, Hohenforst-Schmidt W, Darwiche K, Krauss L, Sparopoulou D, Sakkas L et al. 2-Diethylaminoethyl-dextran methyl methacrylate copolymer nonviral vector: still a long way toward the safety of aerosol gene therapy. Gene Therapy 2013; 20: 1022-8s.
15. Zarogoulidis K, Ziogas E, Boutsikou E, Zarogoulidis P, Darwiche K, Kontakiotis T et al. Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study. Drug Des Dev Ther 2013; 7: 611-617.
16. Hohenforst-Schmidt W, Zarogoulidis P, Darwiche K, Vogl T, Goldberg EP, Huang H et al. Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies. Drug Des Dev Ther 2013; 7: 571-583.
17. Geletneky K, Huesing J, Rommelaere J, Schlehofer JR, Leuchs B, Dahm M et al. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer 2012; 12: 99.
18. Zheng X, Zhou F, Wu B, Chen WR, Xing D. Enhanced tumor treatment using biofunctional indocyanine green-containing nanostructure by intratumoral or intravenous injection. Mol Pharm 2012; 9: 514-522.
19. Macha HN, Freitag L. The role of brachytherapy in the treatment and control of central bronchial carcinoma. Monaldi Arch Chest Dis 1996; 51: 325-328.
20. Freitag L, Ernst A, Thomas M, Prenzel R, Wahlers B, Macha HN. Sequential photodynamic therapy (PDT) and high dose brachytherapy for endobronchial tumour control in patients with limited bronchogenic carcinoma. Thorax 2004; 59: 790-793.
21. Li B, He H, Tao BB, Zhao ZY, Hu GH, Luo C et al. Knockdown of CDK6 enhances glioma sensitivity to chemotherapy. Oncol Rep 2012; 28: 909-914.
22. Xu Y, Zheng W, Wang T, Wang P, Zhu L, Ma X. Genetic protein TmSm(T34A) enhances sensitivity of chemotherapy to breast cancer cell lines as a synergistic drug to doxorubicin. Biomed Pharmacother 2012; 66: 368-372.
23. Xiong J, Sun WJ, Wang WF, Liao ZK, Zhou FX, Kong HY et al. Novel, chimeric, cancer-specific, and radiation-inducible gene promoters for suicide gene therapy of cancer. Cancer 2012; 118: 536-548.
24. Zarogoulidis P, Kontakiotis T, Zarogoulidis K. Inhaled gene therapy in lung cancer: 'as for the future, our task is not to foresee it, but to enable it'. Ther Deliv 2012; 3: 919-921.
25. Darwiche K, Zarogoulidis P, Karamanos NK, Domvri K, Chatzaki E, Constantinidis TC et al. Efficacy versus safety concerns for aerosol chemotherapy in non-smallcell lung cancer: a future dilemma for micro-oncology. Future Oncol 2013; 9: 505-525.
26. Zarogoulidis P, Darwiche K, Hohenforst-Schmidt W, Huang H, Li Q, Freitag L et al. Inhaled gene therapy in lung cancer: proof-of-concept for nano-oncology and nanobiotechnology in the management of lung cancer. Future Oncol 2013; 9: 1171-1194.
27. Chirmule N, Hughes JV, Gao GP, Raper SE, Wilson JM. Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs. J Virol 1998; 72: 6138-6145.
28. Zarogoulidis P, Giraleli C, Karamanos NK. Inhaled chemotherapy in lung cancer: safety concerns of nanocomplexes delivered. Ther Deliv 2012; 3: 1021-1023.
29. Stylianopoulos T. EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors. Ther Deliv 2013; 4: 421-423.
30. Bae YH. Interview with Dr You Han Bae: ligand-mediated versus 'passive' targeting approaches in nanoparticle oncology research. Ther Deliv 2012; 3: 933-936.
31. Yang W, Ahmed M, Elian M, Hady el SA, Levchenko TS, Sawant RR et al. Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model? Radiology 2010; 257: 685-696.
32. Le Pivert PJ, Morrison DR, Haddad RS, Renard M, Aller A, Titus K et al. Percutaneous tumor ablation: microencapsulated echo-guided interstitial chemotherapy combined with cryosurgery increases necrosis in prostate cancer. Technol Cancer Res Treat 2009; 8: 207-216.
33. Lin X, Gao R, Zhang Y, Qi N, Zhang K, He H et al. Lipid nanoparticles for chemotherapeutic applications: strategies to improve anticancer efficacy. Expert Opin Drug Deliv 2012; 9: 767-781.
34. Xie H, Goins B, Bao A, Wang ZJ, Phillips WT. Effect of intratumoral administration on biodistribution of 64Cu-labeled nanoshells. Int J Nanomedicine 2012; 7: 2227-2238.
35. Sim H, Bibee K, Wickline S, Sept D. Pharmacokinetic modeling of tumor bioluminescence implicates efflux, and not influx, as the bigger hurdle in cancer drug therapy. Cancer Res 2011; 71: 686-692.
36. Sharma B, Peetla C, Adjei IM, Labhasetwar V. Selective biophysical interactions of surface modified nanoparticles with cancer cell lipids improve tumor targeting and gene therapy. Cancer Lett 2013; 334: 228-236.
37. Fang J, Qin H, Nakamura H, Tsukigawa K, Shin T, Maeda H. Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention effect in solid tumors. Cancer Sci 2012; 103: 535-541.
38. Zhao W, Zhuang S, Qi XR. Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes. Int J Nanomedicine 2011; 6: 3087-3098.
39. Weibel S, Basse-Luesebrink TC, Hess M, Hofmann E, Seubert C, Langbein-Laugwitz J et al. Imaging of intratumoral inflammation during oncolytic virotherapy of tumors by 19F-magnetic resonance imaging (MRI). PLoS One 2013; 8: e56317.
40. Hecht JR, Farrell JJ, Senzer N, Nemunaitis J, Rosemurgy A, Chung T et al. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc 2012; 75: 332-338.
41. Hanna N, Ohana P, Konikoff FM, Leichtmann G, Hubert A, Appelbaum L et al. Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer. Cancer Gene Ther 2012; 19: 374-381.
42. Leifler KS, Svensson S, Abrahamsson A, Bendrik C, Robertson J, Gauldie J et al. Inflammation induced by MMP-9 enhances tumor regression of experimental breast cancer. J Immunol 2013; 190: 4420-4430.
43. Peng YF, Shi YH, Ding ZB, Zhou J, Qiu SJ, Hui B et al. Alpha-fetoprotein promoterdriven Cre/LoxP-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy. PLoS One 2013; 8: e53072.
44. Chen Q, Cheng P, Song N, Yin T, He H, Yang L et al. Antitumor activity of placentaderived mesenchymal stem cells producing pigment epithelium-derived factor in a mouse melanoma model. Oncol Lett 2012; 4: 413-418.
45. Li H, Nakashima H, Decklever TD, Nace RA, Russell SJ. HSV-NIS an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy. Cancer Gene Ther 2013; 20: 478-485.
46. Hallett MA, Teng B, Hasegawa H, Schwab LP, Seagroves TN, Pourmotabbed T. Anti-matrix metalloproteinase-9 DNAzyme decreases tumor growth in the MMTVPyMT mouse model of breast cancer. Breast Cancer Res 2013; 15: R12.
47. Puntel M, AKM GM, Farrokhi C, Vanderveen N, Paran C, Appelhans A et al. Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma. Toxicol Appl Pharmacol 2013; 268: 318-330.
48. Huang S, Shao K, Kuang Y, Liu Y, Li J, An S et al. Tumor targeting and microenvironment-responsive nanoparticles for gene delivery. Biomaterials 2013; 34: 5294-5302.
49. Ramachandran M, Yu D, Wanders A, Essand M, Eriksson F. An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil- activating protein with therapeutic effects on neuroendocrine tumors. Mol Ther 2013; 21: 2008-2018.
50. Kasai K, Nakashima H, Liu F, Kerr S, Wang J, Phelps M et al. Toxicology and biodistribution studies for MGH2.1, an oncolytic virus that expresses two prodrug-activating genes, in combination with prodrugs. Mol Ther Nucleic Acids 2013; 2: e113.
51. Choi IK, Strauss R, Richter M, Yun CO, Lieber A. Strategies to increase drug penetration in solid tumors. Front Oncol 2013; 3: 193.
52. Govindarajan S, Sivakumar J, Garimidi P, Rangaraj N, Kumar JM, Rao NM et al. Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-affibody bioconjugate. Biomaterials 2012; 33: 2570-2582.
53. Gopal V, Guruprasad K. Structure prediction and validation of an affibody engineered for cell-specific nucleic acid targeting. Syst Synth Biol 2010; 4: 293-297.
54. Zarogoulidis P, Darwiche K, Krauss L, Huang H, Zachariadis GA, Katsavou A et al. Inhaled cisplatin deposition and distribution in lymph nodes in stage II lung cancer patients. Future Oncol 2013; 9: 1307-1313.
55. Zarogoulidis P, Petridis D, Ritzoulis C, Darwiche K, Spyratos D, Huang H et al. Establishing the optimal nebulization system for paclitaxel, docetaxel, cisplatin, carboplatin and gemcitabine: back to drawing the residual cup. Int J Pharm 2013; 453: 480-487.
56. Peiris PM, Bauer L, Toy R, Tran E, Pansky J, Doolittle E et al. Enhanced delivery of chemotherapy to tumors using a multicomponent nanochain with radiofrequency- tunable drug release. ACS Nano 2012; 6: 4157-4168.
57. Liu Q, Li R, Zhu Z, Qian X, Guan W, Yu L et al. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles. Int J Pharm 2012; 430: 350-358.
58. Luo X, Xu G, Song H, Yang S, Yan S, Jia G et al. Promoted antitumor activities of acid-labile electrospun fibers loaded with hydroxycamptothecin via intratumoral implantation. Eur J Pharm Biopharm 2012; 82: 545-553.
59. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998; 95: 4607-4612.
60. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2011; 2: 281-298.
61. Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, di Tomaso E et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci USA 2001; 98: 4628-4633.
62. Peracchia MT, Fattal E, Desmaele D, Besnard M, Noel JP, Gomis JM et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release 1999; 60: 121-128.
63. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B et al. Renal clearance of quantum dots. Nat Biotechnol 2007; 25: 1165-1170.
64. Chauhan VP, Popovic Z, Chen O, Cui J, Fukumura D, Bawendi MG et al. Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed Engl 2011; 50: 11417-11420.
65. Dellian M, Yuan F, Trubetskoy VS, Torchilin VP, Jain RK. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br J Cancer 2000; 82: 1513-1518.
66. Stylianopoulos T, Soteriou K, Fukumura D, Jain RK. Cationic nanoparticles have superior transvascular flux into solid tumors: insights from a mathematical model. Ann Biomed Eng 2013; 41: 68-77.
67. Kale AA, Torchilin VP. Environment-responsive multifunctional liposomes. Methods Mol Biol 2010; 605: 213-242.
68. Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, Jiang W et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci USA 2011; 108: 2426-2431.
69. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-1461.
70. Ferretti S, Allegrini PR, Becquet MM, McSheehy PM. Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics. Neoplasia 2009; 11: 874-881.
71. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21: 418-429.
72. van der Veldt AA, Smit EF, Lammertsma AA. Positron emission tomography as a method for measuring drug delivery to tumors in vivo: the example of [(11)C]docetaxel. Front Oncol 2013; 3: 208.
73. Zou Y, Tornos C, Qiu X, Lia M, Perez-Soler R. p53 aerosol formulation with low toxicity and high efficiency for early lung cancer treatment. Clin Cancer Res 2007; 13: 4900-4908.
74. Frederiksen KS, Abrahamsen N, Cristiano RJ, Damstrup L, Poulsen HS. Gene delivery by an epidermal growth factor/DNA polyplex to small cell lung cancer cell lines expressing low levels of epidermal growth factor receptor. Cancer Gene Ther 2000; 7: 262-268.
75. Kim HW, Park IK, Cho CS, Lee KH, Beck Jr GR, Colburn NH et al. Aerosol delivery of glucosylated polyethylenimine/phosphatase and tensin homologue deleted on chromosome 10 complex suppresses Akt downstream pathways in the lung of K-ras null mice. Cancer Res 2004; 64: 7971-7976.
76. Gautam A, Densmore CL, Melton S, Golunski E, Waldrep JC. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther 2002; 9: 28-36.
77. Horev-Drori G, Cooks T, Bittan H, Lazarov E, Schmidt M, Arazi L et al. Local control of experimental malignant pancreatic tumors by treatment with a combination of chemotherapy and intratumoral 224radium-loaded wires releasing alpha-emitting atoms. Transl Res 2012; 159: 32-41.
78. Ahmed M, Moussa M, Goldberg SN. Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation. Chem Phys Lipids 2012; 165: 424-437.
79. Son CH, Shin DY, Kim SD, Park HS, Jung MH, Bae JH et al. Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model. J Immunother 2012; 35: 607-614.
80. Raut CP, Boucher Y, Duda DG, Morgan JA, Quek R, Ancukiewicz M et al. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One 2012; 7: e26331.
81. Betting DJ, Hurvitz SA, Steward KK, Yamada RE, Kafi K, van Rooijen N et al. Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma. J Immunother 2012; 35: 534-543.
82. Lai CY, Fite BZ, Ferrara KW. Ultrasonic enhancement of drug penetration in solid tumors. Front Oncol 2013; 3: 204.
83. Zhao N, Yang B, Duan YC, Lei R. [Comparative study on five pretreatment methods for ICP-OES determination of mineral elements in Rosa rugosa]. Guang Pu Xue Yu Guang Pu Fen Xi 2011; 31: 2256-2258.
84. Correa AH, Choi MR, Gironacci M, Aprile F, Fernandez BE. Atrial natriuretic factor decreases renal dopamine turnover and catabolism without modifying its release. Regul Pept 2008; 146: 238-242.
85. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol 2007; 18: 2968-2974.
86. Kim JH, Lee Y, Bae YS, Kim WS, Kim K, Im HY et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 2007; 125: 257-267.
87. Jang EY, Lee SO, Choi SH, Sung H, Kim MN, Kim BJ et al. Case of pyomyositis due to Mycobacterium haemophilum in a renal transplant recipient. J Clin Microbiol 2007; 45: 3847-3849.
88. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L et al. Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci USA 2004; 101: 10380-10385.
89. Eshita Y, Higashihara J, Onishi M, Mizuno M, Yoshida J, Takasaki T et al. Mechanism of introduction of exogenous genes into cultured cells using DEAEdextran- MMA graft copolymer as non-viral gene carrier. Molecules 2009; 14: 2669-2683.
90. Onishi Y, Eshita Y, Murashita A, Mizuno M, Yoshida J. Synthesis and characterization of 2-diethyl-aminoethyl-dextran-methyl methacrylate graft copolymer for nonviral gene delivery vector. J Appl Polym Sci 2005; 98: 9-14.
91. Bertram JS, Janik P. Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture. Cancer Lett 1980; 11: 63-73.